Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.66
(-1.37%)
CNY 21.66
(-1.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.17 Billion CNY | 15.84% |
| 2022 | 1.01 Billion CNY | 29.17% |
| 2021 | 788.93 Million CNY | 19.8% |
| 2020 | 658.56 Million CNY | -29.95% |
| 2019 | 940.08 Million CNY | 384.82% |
| 2018 | 193.9 Million CNY | 76.25% |
| 2017 | 110.02 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 262.43 Million CNY | 12.47% |
| 2024 Q1 | 266.55 Million CNY | -34.33% |
| 2024 Q2 | 239.91 Million CNY | -9.99% |
| 2023 Q2 | 269.03 Million CNY | 6.53% |
| 2023 FY | 1.18 Billion CNY | 15.84% |
| 2023 Q3 | 276.93 Million CNY | 2.94% |
| 2023 Q1 | 252.53 Million CNY | -10.91% |
| 2023 Q4 | 405.88 Million CNY | 46.56% |
| 2022 Q3 | 292.46 Million CNY | 34.16% |
| 2022 Q2 | 217.98 Million CNY | -3.17% |
| 2022 Q1 | 225.13 Million CNY | -13.75% |
| 2022 FY | 1.01 Billion CNY | 29.17% |
| 2022 Q4 | 283.46 Million CNY | -3.08% |
| 2021 FY | 788.93 Million CNY | 19.8% |
| 2021 Q4 | 261.02 Million CNY | 45.91% |
| 2021 Q3 | 178.89 Million CNY | -6.1% |
| 2021 Q2 | 190.52 Million CNY | 20.22% |
| 2021 Q1 | 158.48 Million CNY | -13.43% |
| 2020 Q4 | 183.07 Million CNY | -8.13% |
| 2020 Q3 | 199.28 Million CNY | 0.0% |
| 2020 FY | 658.56 Million CNY | -29.95% |
| 2019 FY | 940.08 Million CNY | 384.82% |
| 2018 FY | 193.9 Million CNY | 76.25% |
| 2017 FY | 110.02 Million CNY | 0.0% |